Lupin Limited reported robust financial growth for the year ended March 31, 2026, with a consolidated net profit of ₹53,554.7 million, a significant increase from ₹33,062.6 million in the previous year. Driven by strong pharmaceutical performance, the Board has recommended a dividend of ₹18 per share (900% of face value), subject to shareholder approval at the upcoming Annual General Meeting.
Financial Highlights
Lupin Limited achieved substantial growth in the 2026 fiscal year, recording total revenue from operations of ₹279,580.3 million compared to ₹227,079.0 million in 2025. The company’s profit before tax reached ₹68,725.5 million, highlighting a strong operational performance across its business segments. For the final quarter (Q4) ended March 31, 2026, the company reported a consolidated net profit of ₹14,686.7 million.
Strategic Business Performance
The Pharmaceuticals segment remained the primary growth engine, generating ₹278,123.6 million in annual revenue. The company continued to expand its global footprint and product portfolio, evidenced by the acquisition of VISUfarma B.V. for ₹20,902.7 million and the integration of Renascience Pharma Limited, which contributed to its broader R&D and market capabilities.
Dividend and Shareholder Value
Reflecting the company’s strong financial health and confidence in future cash flows, the Board of Directors has recommended a dividend of ₹18 per equity share, having a face value of ₹2 each. This payout, amounting to an aggregate of ₹8,229.2 million, is subject to the approval of shareholders at the upcoming Annual General Meeting. Additionally, the company saw equity expansion through the allotment of 614,066 equity shares during the year following the exercise of employee stock options.
Future Outlook
Lupin continues to focus on operational efficiency and addressing regulatory requirements in global markets. Despite provisions for various litigation matters, the company maintains a robust balance sheet with total assets reaching ₹383,648.3 million. The company remains committed to long-term value creation through strategic divestments, such as the transfer of its OTC and API R&D businesses, and ongoing investments in its pipeline.
Source: BSE
